[A randomized, controlled, multicenter clinical trial comparing pemetrexed/cisplatin and gemcitabine/cisplatin as first-line treatment for advanced nonsquamous non-small cell lung cancer]
Yan Huang, Yunpeng Liu, Jianying Zhou, Nong Xu, Baolan Li, Gang Wu, Jian Fang, Kai Li, Xiaoqing Liu, Wei Liu, You Lu, Mengzhao Wang, Wenchao Liu, Houjie Liang, Yiping Zhang, Cheng Huang, Shunjin Wang, Yajie Wang, Shiying Yu, Jianhua Chang, Zhehai Wang, Zhihuang Hu, Li Zhang, Yan Huang, Yunpeng Liu, Jianying Zhou, Nong Xu, Baolan Li, Gang Wu, Jian Fang, Kai Li, Xiaoqing Liu, Wei Liu, You Lu, Mengzhao Wang, Wenchao Liu, Houjie Liang, Yiping Zhang, Cheng Huang, Shunjin Wang, Yajie Wang, Shiying Yu, Jianhua Chang, Zhehai Wang, Zhihuang Hu, Li Zhang
Abstract
Background and objective: Platinum-based doublet chemotherapy is still the standard first-line treatment for non-small cell lung cancer (NSCLC). Previous studies have demonstrated that pemetrexed combined with platinum had promising efficacy and safety profile in NSCLC, especially in patients with nonsquamous NSCLC. This trial was conducted to evaluate the efficacy and safety of pemetrexed made in China as first-line treatment.
Methods: The present study was a randomized, controlled, multicenter clinical trial. Patients were randomly assigned (1:1) to receive cisplatin plus pemetrexed chemotherapy (PC group) or gemcitabine plus cisplatin (GC group) every 3 weeks. The primary end point was progression free survival (PFS) and the secondary end points included 1 year survival rate, objective response rate (ORR), survival without grade 3/4 toxicity (SWT3/4) and safety profile.
Results: A total of 288 patients from 20 institutions across China were enrolled into the study. Based on the Full Analyses Set (FAS), the PFS was 168 days (5.6 months) vs 140 days (4.7 months) (P=0.16), one year survival rate was 50.0% vs 54.9% (P=0.47), ORR was 24.4% vs 14.2% (P=0.06) in the PC group and the GC group, respectively; Survival without grade 3/4 toxicity was 11.3 months in GC group vs 8.1 months in PC group (P=0.23). In terms of the safety, side effects were less observed on the PC group (81.95% vs 93.75%, P=0.003). The main side effects included leukopenia, neutropenia, emesis, anemia, thrombopenia.
Conclusions: The both regimens have similar efficacy as the treatment for advanced nonsquamous NSCLC, but pemetrexed plus cisplatin regimen has better safety profile and seems to have longer PFS, which makes it a new option as the first line setting.
Trial registration: ClinicalTrials.gov NCT01194453.
Figures
References
- Azzoli CG, Baker S Jr, Temin S, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage Ⅳ non-small-cell lung cancer. J Clin Oncol. 2009;27(36):6251–6266. doi: 10.1200/JCO.2009.23.5622.
- Bonomi P, Kim K, Fairclough D, et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2000;18(3):623–631. doi: 10.1200/JCO.2000.18.3.623.
- Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92–98. doi: 10.1056/NEJMoa011954.
- Goldstraw P, Ball D, Jett J R, et al. Non-small-cell lung cancer. Lancet. 2011;378(9804):1727–1740. doi: 10.1016/S0140-6736(10)62101-0.
- Pallis AG, Georgoulias V. Is there a standard regimen for first-line treatment of advanced/metastatic non-small-cell lung cancer? What has meta-analyses contributed to today' s standard of care. Lung Cancer. 2012;75(3):269–274. doi: 10.1016/j.lungcan.2011.09.010.
- Scagliotti GV, Parikh P, von Pawel J, et al. Phase Ⅲ study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3543–3551. doi: 10.1200/JCO.2007.15.0375.
- Hanna N, Shepherd FA, Fossella FV, et al. Randomized Phase Ⅲ trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22(9):1589–1597. doi: 10.1200/JCO.2004.08.163.
- Gronberg BH, Bremnes RM, Flotten O, et al. Phase Ⅲ study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2009;27(19):3217–3224. doi: 10.1200/JCO.2008.20.9114.
Horner M R L K M. SEER Cancer Statistics Review, 1975-2006 (Vintage 2009 Populations), National Cancer Institute. http://seer.cancer.gov/csr/1975_2009_pops09/.
- Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase Ⅲ study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636–2644. doi: 10.1200/JCO.2003.11.136.
- Scagliotti GV, Kortsik C, Dark GG, et al. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, Phase Ⅱ trial. . Clin Cancer Res. 2005;11(2 Pt 1):690–696.
- Zinner RG, Fossella FV, Gladish GW, et al. Phase Ⅱ study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer. 2005;104(11):2449–2456. doi: 10.1002/(ISSN)1097-0142.
- Scagliotti GV, Park K, Patil S, et al. Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaive patients with advanced non-small cell lung cancer: a risk-benefit analysis of a large Phase Ⅲ study. Eur J Cancer. 2009;45(13):2298–2303. doi: 10.1016/j.ejca.2009.04.033.
Source: PubMed